Tenaya Therapeutics, Inc. Common Stock (TNYA) is a publicly traded Healthcare sector company. As of May 21, 2026, TNYA trades at $0.79 with a market cap of $169.91M and a P/E ratio of -1.74. TNYA moved +2.73% today. Year to date, TNYA is +10.94%; over the trailing twelve months it is +69.73%. Its 52-week range spans $0.36 to $4.01. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces TNYA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tenaya to Reveal One-Year TN-401 ARVC Data and Q2 MyPEAK-1 Updates: Tenaya Therapeutics reported Q1 2026 results and announced it will present one-year Cohort 1 plus initial Cohort 2 RIDGE-1 TN-401 data at ASGCT May 15; interim MyPEAK-1 TN-201 data from 3E13 and 6E13 vg/kg cohorts due in Q2 2026. It also advanced TN-301 DMD data and began Alnylam collaboration.
| Metric | Value |
|---|---|
| Price | $0.79 |
| Market Cap | $169.91M |
| P/E Ratio | -1.74 |
| EPS | $-0.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.01 |
| 52-Week Low | $0.36 |
| Volume | 53.22K |
| Avg Volume | 0 |
| Revenue (TTM) | $225.00K |
| Net Income | $-83.00M |
| Gross Margin | 0.00% |
6 analysts cover TNYA: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.